Home > Boards > US Listed > Medical - Drugs > AVEO Pharmaceuticals, Inc. (AVEO)

A 3.6% increase on today's low from Friday's

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Biotech Pharmer Member Profile
 
Followed By 3
Posts 1,846
Boards Moderated 0
Alias Born 09/16/05
160x600 placeholder
AVEO Announces Presentation of Updated OS and Subgroup Data from Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma Business Wire - 11/18/2019 6:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/12/2019 7:16:33 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 11/12/2019 7:15:55 AM
AVEO Reports Third Quarter 2019 Financial Results and Provides Business Update Business Wire - 11/12/2019 7:00:00 AM
AVEO Oncology & Biodesix Announce Initiation of the CyFi-2 Study, a Phase 2 Randomized Study of Ficlatuzumab in Combination w... Business Wire - 11/7/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 11/5/2019 7:02:44 AM
AVEO Oncology Announces Regulatory Update for Tivozanib in Renal Cell Carcinoma Business Wire - 11/4/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 10/3/2019 9:12:29 AM
AVEO Oncology Announces Initiation of Enrollment in Phase 1b/2 Study of FOTIVDA® (tivozanib) in Combination with IMFINZI® (... Business Wire - 9/30/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/27/2019 7:24:47 AM
AVEO Oncology to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference Business Wire - 9/26/2019 7:00:00 AM
AVEO Oncology & EUSA Pharma Announce Presentation of Final PFS Results from Phase 2 Portion of the TiNivo Study in Renal Cell... Business Wire - 9/23/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/17/2019 5:23:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/12/2019 4:11:14 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/10/2019 9:44:00 AM
AVEO Oncology Announces Updated Overall Survival Hazard Ratio of 0.99 in Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carc... Business Wire - 9/10/2019 6:30:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/27/2019 5:26:52 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/8/2019 7:06:22 AM
AVEO Reports Second Quarter 2019 Financial Results and Provides Business Update Business Wire - 8/8/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 8/1/2019 6:16:14 AM
Kyowa Kirin Buys Back Tivozanib Non-Oncology Rights from AVEO Oncology Business Wire - 8/1/2019 6:00:00 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 6/14/2019 8:03:55 AM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:02:14 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:01:28 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/13/2019 5:01:26 PM
Biotech Pharmer   Monday, 10/21/19 04:14:36 PM
Re: None
Post # of 5107 
A 3.6% increase on today's low from Friday's low. This continues confirming Clay's reversal strength parameter. More nervous "scam" and "turd" laughter is emanating from the peanut gallery. LOL.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist